Neogenomics pres. Stone sells $277k in NEO stock
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
NeoGenomics Inc (NEO)
Assess today's live NeoGenomics Inc (NEO) share price, performance and insights using our live NASDAQ: NEO stock exchange data.
Analyse the historical data and NeoGenomics Inc share price performance charts on this page. Our technical summary section provides analysis on NeoGenomics share price buy/sell indicators using real-time data (or discuss the NeoGenomics (NEO) stock price today with other investors in the NeoGenomics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ NEO share price (ISIN: US64049M2098) to enhance your trading decisions with our free investment tools and resources.
What Is the NeoGenomics Inc Share Price Today?
The NeoGenomics share price today is 12.31.
What Is the Stock Symbol for NeoGenomics Inc
The stock symbol (or 'ticker') for NeoGenomics Inc is "NEO."
What Stock Exchange Does NeoGenomics Inc Trade On?
NeoGenomics Inc is listed and trades on the NASDAQ stock exchange.
Is NeoGenomics Inc a Good Stock to Buy?
Determining whether NeoGenomics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and NeoGenomics Inc share price performance charts on this page. Our technical summary section provides analysis on NeoGenomics share price buy/sell indicators using real-time data (or discuss the NeoGenomics (NEO) stock price today with other investors in the NeoGenomics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ NEO share price (ISIN: US64049M2098) to enhance your trading decisions with our free investment tools and resources.
What Is the NeoGenomics Inc Share Price Today?
The NeoGenomics share price today is 12.31.
What Is the Stock Symbol for NeoGenomics Inc
The stock symbol (or 'ticker') for NeoGenomics Inc is "NEO."
What Stock Exchange Does NeoGenomics Inc Trade On?
NeoGenomics Inc is listed and trades on the NASDAQ stock exchange.
Is NeoGenomics Inc a Good Stock to Buy?
Determining whether NeoGenomics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.06
12.33
52 wk Range
4.72
14.73
Earnings results expected in 14 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.0612.33
52 wk Range
4.7214.73
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NEO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
14.43
Upside
+17.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Form 8K NeoGenomics Inc For: 30 December
- Investing.com
- Neogenomics pres. Stone sells $277k in NEO stock
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
NeoGenomics Company Profile
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics Inc SWOT Analysis
Strategic Crossroads | Neo Performance Materials faces pivotal decisions as it navigates market challenges and explores strategic alternatives, potentially reshaping its future in advanced materials |
European Expansion | Delve into Neo's new agreement with a major European automotive supplier, signaling growth potential in the electric vehicle and green technology sectors |
Market Dynamics | Explore the complexities of the rare earths market, including geopolitical factors, supply chain challenges, and Neo's positioning amidst industry volatility |
Financial Outlook | Analysts project positive earnings for Neo, with Stifel setting a C$13.00 price target. The company's strategic review remains the primary value drive |
NeoGenomics Inc Earnings Call Summary for Q3/2025
- NeoGenomics reported Q3 2025 EPS of $0.03, beating $0.02 forecast; revenue reached $188M, up 12% YoY
- Stock surged 8.07% pre-market to $10.98; company maintains strong financial health with 4x liquid assets to short-term obligations
- NGS revenues grew 24% YoY, now 33% of clinical revenue; MRD segment shows strong growth potential
- Full-year 2025 revenue guidance set at $720M-$726M, indicating 9-10% growth; Radar ST assay launch planned for Q1 2026
- Company faces challenges in MRD market penetration and integration of newly acquired Pathline lab
Last Updated: 28/10/2025, 13:50
Read Full TranscriptCompare NEO to Peers and Sector
Metrics to compare | NEO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNEOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.0x | −6.0x | −0.6x | |
PEG Ratio | 0.31 | −0.41 | 0.00 | |
Price/Book | 1.9x | 2.2x | 2.6x | |
Price / LTM Sales | 2.2x | 4.3x | 3.4x | |
Upside (Analyst Target) | 16.1% | 19.2% | 44.9% | |
Fair Value Upside | Unlock | −13.6% | 6.3% | Unlock |
Analyst Ratings
6 Buy
7 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 14.43
(+17.21% Upside)
Earnings
Latest Release
Oct 28, 2025
EPS / Forecast
0.03 / 0.02
Revenue / Forecast
187.80M / 183.74M
People Also Watch
FAQ
What Is the NeoGenomics (NEO) Share Price Today?
The live NeoGenomics share price today is 12.31
What Stock Exchange Does NeoGenomics (NEO) Trade On?
NeoGenomics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for NeoGenomics?
The stock symbol (also called a 'ticker') for NeoGenomics is "NEO."
What Is the Current NeoGenomics Market Cap?
As of today, NeoGenomics market capitalisation is 1.59B.
What Is NeoGenomics's (NEO) Earnings Per Share (TTM)?
The NeoGenomics EPS is currently -0.89 (Trailing Twelve Months).
When Is the Next NeoGenomics Earnings Date?
NeoGenomics's next earnings report will be released on 17 Feb 2026.
Is NEO a Buy or Sell From a Technical Analyst Perspective?
Based on today's NeoGenomics moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has NeoGenomics Stock Split?
NeoGenomics has split 2 times. (See the NEO stock split history page for full effective split date and price information.)
How Many Employees Does NeoGenomics Have?
NeoGenomics has 2200 employees.
What is the current trading status of NeoGenomics (NEO)?
As of 03 Feb 2026, NeoGenomics (NEO) is trading at a price of 12.31, with a previous close of 12.06. The stock has fluctuated within a day range of 12.06 to 12.33, while its 52-week range spans from 4.72 to 14.73.
What Is NeoGenomics (NEO) Price Target According to Analysts?
The average 12-month price target for NeoGenomics is USD14.43, with a high estimate of USD17 and a low estimate of USD12. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +17.21% Upside potential.
What Is the NEO Premarket Price?
NEO's last pre-market stock price is 11.92. The pre-market share volume is 3,520.00, and the stock has decreased by -0.14, or -1.16%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.